Hotline: 1800 102 2007
Search Business Opportunities
Merger 26 Mar 2015

Sun Pharma to delist Ranbaxy from BSE post completion of $4 billion merger

With the completion of $4 billion acquiring of Ranbaxy by Sun Pharma, shareholders of the former are expected to receive 0.8 share of Sun Pharma for each share of Ranbaxy.

Sun Pharmaceutical announced that Ranbaxy will be delisted from the Indian Stock Exchange as their $4 billion merger is completing.

Reportedly, while filing to the BSE, Sun Pharma said, “Following the closure of this transaction, Ranbaxy will be delisted from the Indian Stock Exchanges. Ranbaxy shareholders will receive 0.8 share of Sun Pharma for each share of Ranbaxy.”

Worth mentioning here is the fact that the merger has fortified Sun Pharma’s position as the world’s fifth largest speciality generic pharmaceutical firm and the top ranking Indian Pharma Company with significant lead in market share, added the brand.

Commenting on the matter, Dilip Shanghvi, MD, Sun Pharma said, “We will continue to focus on gaining trust of the regulators globally while continuing to develop products based on patient needs and leverage them to become brand leaders globally.”

The combined entity’s manufacturing footprint covers five continents with products sold in over 150 nations with a stronger presence in the US, India, Asia, Europe, South Africa, CIS & Russia and Latin America.

Post-merger, Daiichi Sankyo becomes the second largest shareholder in Sun Pharma and both the companies will work together to leverage this relationship for global business growth, said Sun Pharma.

Meanwhile, Sun Pharma Chairman Israel Makov said, “The combined entity will capitalize on the expanded global footprint and enhance our dominance as a world leader in the speciality generics landscape.”

Ranbaxy has been facing issues raised by the FDA, US authorities and health regulators in the European markets.

In 2013, it had pleaded guilty to ‘felony charges’ relating to manufacture and distribution of certain adulterated drugs made at two India units, the US subsidiary of Ranbaxy had agreed to pay $500 million in settlement with the US authorities.

Significantly, Sun Pharma said three key priority levers to drive growth in the combined entity have been identified which includes achieving 100 per cent compliance in manufacturing in line with Regulator expectations, increase R&D productivity to introduce new innovative products and strong business growth across the US, India, and rest of the world markets.

Related opportunities
  • Others Food Service
    Be a Part of Growth Story by joining hands with..
    Locations looking for expansion Madhya Pradesh
    Establishment year 2015
    Franchising Launch Date 2016
    Investment size Rs. 5lac - 10lac
    Space required 200 - 3000 Sq.ft
    Franchise Outlets -NA-
    Franchise Type Unit, Multiunit
    Headquater Indore Madhya Pradesh
  • About:Agent Jack's Bar is a casual dining restaurant that serves..
    Locations looking for expansion Maharashtra
    Establishment year 2016
    Franchising Launch Date 2017
    Investment size Rs. 2 Cr. - 5 Cr
    Space required -NA-
    Franchise Outlets -NA-
    Franchise Type Unit, Multiunit
    Headquater Mumbai City Maharashtra
  • Ayurvedic, Herbal & Organic Products
    Located in the heart of the city, ARTH ranks among..
    Locations looking for expansion Karnataka
    Establishment year 1999
    Franchising Launch Date 2015
    Investment size Rs. 10lac - 20lac
    Space required 1000- 1200 Sq ft
    Franchise Outlets -NA-
    Franchise Type Unit
    Headquater Bangalore Urban District Karnataka
  • Kids & Children clothing
    About:1st Step as the name suggests is all about making..
    Locations looking for expansion Tamil Nadu
    Establishment year 2002
    Franchising Launch Date 2017
    Investment size Rs. 30lac - 50lac
    Space required 1000 - Sq.ft
    Franchise Outlets -NA-
    Franchise Type Unit, Multiunit
    Headquater Chennai Tamil Nadu
Insta-Subscribe to
The Franchising World
For hassle free instant subscription, just give your number and email id and our customer care agent will get in touch with you
OR Click here to Subscribe Online
Daily Updates
Submit your email address to receive the latest updates on news & host of opportunities
More Stories